Lars Henrik Myklebust, Desiree Eide, Espen A Arnevik, Omid Dadras, Silvana De Pirro, Rune Ellefsen, Lars T Fadnes, Morten Hesse, Timo L Kvamme, Francesca Melis, Ann Oldervoll, Birgitte Thylstrup, Linda E C Wusthoff, Thomas Clausen
BACKGROUND: Opioid agonist treatment (OAT) for patients with opioid use disorder (OUD) has a convincing evidence base, although variable retention rates suggest that it may not be beneficial for all. One of the options to include more patients is the introduction of heroin-assisted treatment (HAT), which involves the prescribing of pharmaceutical heroin in a clinical supervised setting. Clinical trials suggest that HAT positively affects illicit drug use, criminal behavior, quality of life, and health...
March 29, 2024: BMC Health Services Research